ARTICLE | Finance

Celling the liver

Belgian cell therapy play Promethera raises $31M in venture round, loan

April 2, 2012 7:00 AM UTC

Alain Parthoens of Vesalius Biocapital Partners hopes the Orphan disease focus of adult stem cell company Promethera Biosciences S.A. will help it achieve what another of his stem cell investments has struggled to get - reimbursement.

Last week, the Belgian biotech raised €17 million ($22.5 million) in a series B round. New investors were Boehringer Ingelheim Venture Fund; the venture arm of Shire plc (LSE:SHP; NASDAQ:SHPGY); Mitsui Global Investment; ATMI (NASDAQ:ATMI); and Sambrinvest...